By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Taisho Pharmaceutical Co., Inc. 

24-1, Takada 3-Chome

Toshima-ku  Tokyo  170-8633  Japan
Phone: 81-0-3-39851111 Fax: 81-0-3-39858627


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Merck & Co.  Neuroscience

Pharmagene Laboratories Limited 





Company News
Taisho Pharmaceutical Leads Bids For India's Paras Pharmaceuticals Ltd. 10/6/2010 7:54:24 AM
Bristol-Myers Squibb Company (BMY) (JOBS) Sells Asia Rights to Japan's Taisho Pharmaceutical for $310 Million 9/16/2009 7:02:01 AM
Chugai Pharmaceutical Co., Ltd. (Japan) and Taisho Pharmaceutical Release: Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial 12/18/2008 8:49:44 AM
Pfizer Inc. (PFE) and Taisho Pharmaceutical Finalize Deal on Schizophrenia Drug; Pfizer to Pay Initial $22M 1/7/2008 6:21:24 AM
Pfizer Inc. (PFE) Signs Deal for Taisho Pharmaceutical's Schizophrenia Drug 10/30/2007 7:08:55 AM
BrainCells Inc. and Taisho Pharmaceutical Sign Licensing Agreement for Novel CNS Program 9/27/2007 7:41:23 AM
Indigo Pharmaceuticals, Inc. Signs License Agreement for INDI-702, a Drug for the Treatment of Arteriosclerosis Obliterans, With Nissan Chemical Industries, Ltd. and Taisho Pharmaceutical 6/1/2007 11:07:44 AM
Chugai Pharmaceutical Co., Ltd. (Japan) Announces Co-Development And Co-Marketing Agreement With Taisho Pharmaceutical For The Antiresorptive Bisphosphonate R484 9/12/2006 2:12:37 PM
The Day In Review: Immunicon Corporation (IMMC) Rises On AstraZeneca PLC (AZN) Deal 8/7/2006 5:02:04 PM
Taisho Pharmaceutical And Eli Lilly and Company (LLY) Terminate A License Agreement For Taisho's Potential New Drug For Treatment Of Type 2 Diabetes 8/7/2006 10:37:41 AM
123
//-->